6
Feb
2017
A Canadian Biotech Breakaway?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Feb
2017
Hiring Women Execs in Biotech, VC Firms is a Moneyball Play (Part 1): Getting Better Returns
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jan
2017
Drug Delivery Devices Tantalize with Promise in Adherence, Local Delivery and Personalization
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2017
J&J Reels in Actelion for $30B, Celgene Snaps up Delinia, and an IPO Flurry
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jan
2017
Conversation with Steve Miller on The Evolving Relationship of PBMs and Biopharma (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2017
Conversation with Steve Miller of Express Scripts (Part 1)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jan
2017
Women Making Progress, Very Slowly, On Biotech Boards, Report Says
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jan
2017
It Takes Two: Universities and Industry Can Work Together to Fix the PhD Job Market
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2017
Who’s In and Out on Trump’s Health Team, BMS Cedes Ground to Merck, & CRE Superbugs on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2017
Takeda Leans on a Little Guy, Ovid Therapeutics, to Go the Distance With an Epilepsy Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2017
Takeda Takes Out Ariad, Illumina Plants a $100 Genome Stake, & Anti-Vaxxer Nuzzles With Trump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jan
2017
Brace Yourselves, Pharma – Trump’s Coming After You
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jan
2017
It’s Time for Biopharma to Promote Public Health
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jan
2017
Amgen Wins PCSK9 Duel, Jenkins’ Parting Shot, and Obamacare’s Last Stand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2016
Big RNA Day For Spinraza, Cempra Stumbles, and Intarcia Rakes in More Loot
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Dec
2016
Senators Dial Up the Heat, the Overblown CRISPR Case, & Biogen’s New CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Dec
2016
Unfashionable Science, and a Daring Model for Alzheimer’s, Without VCs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Dec
2016
Merck Thumps Gilead in Court, Genentech’s New CEO, Alexion Turmoil
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2016
Trump Vows Drug Price Clampdown, A Wackadoodle FDA Boss, & Alzheimer’s Heat
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.